137 related articles for article (PubMed ID: 34070797)
1. How Has Prostate Cancer Radiotherapy Changed in Italy between 2004 and 2011? An Analysis of the National Patterns-Of-Practice (POP) Database by the Uro-Oncology Study Group of the Italian Society of Radiotherapy and Clinical Oncology (AIRO).
Mazzeo E; Triggiani L; Frassinelli L; Guarneri A; Bartoncini S; Antognoni P; Gottardo S; Greco D; Borghesi S; Nanni S; Bruni A; Ingrosso G; D'Angelillo RM; Detti B; Francolini G; Magli A; Guerini AE; Arcangeli S; Spiazzi L; Ricardi U; Lohr F; Magrini SM
Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34070797
[TBL] [Abstract][Full Text] [Related]
2. Image-guided dose-escalated radiation therapy for localized prostate cancer with helical tomotherapy.
Barelkowski T; Wust P; Kaul D; Zschaeck S; Wlodarczyk W; Budach V; Ghadjar P; Beck M
Strahlenther Onkol; 2020 Mar; 196(3):229-242. PubMed ID: 31873779
[TBL] [Abstract][Full Text] [Related]
3. PROLAPSE: survey about local prostate cancer relapse salvage treatment with external beam re-irradiation: results of the Italian Association of Radiotherapy and Clinical Oncology (AIRO).
Zerini D; Jereczek-Fossa BA; Ciabattoni A; Mirri A; Bertoni F; Fersino S; D'Agostino G; Lohr F; Mortellaro G; Triggiani L; Marvaso G; Pepa M; Cuccia F; Alongi F;
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2311-2317. PubMed ID: 32583236
[TBL] [Abstract][Full Text] [Related]
4. Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer.
Zelefsky MJ; Kollmeier M; Cox B; Fidaleo A; Sperling D; Pei X; Carver B; Coleman J; Lovelock M; Hunt M
Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):125-9. PubMed ID: 22330997
[TBL] [Abstract][Full Text] [Related]
5. Radiotherapy for prostate cancer - Does daily image guidance with tighter margins improve patient reported outcomes compared to weekly orthogonal verified irradiation? Results from a randomized controlled trial.
Tøndel H; Lund JÅ; Lydersen S; Wanderås AD; Aksnessæther B; Jensen CA; Kaasa S; Solberg A
Radiother Oncol; 2018 Feb; 126(2):229-235. PubMed ID: 29398152
[TBL] [Abstract][Full Text] [Related]
6. Changes in patterns of practice for prostate cancer radiotherapy in Italy 1995-2003. A survey of the Prostate Cancer Study Group of the Italian Radiation Oncology Society.
Pegurri L; Buglione M; Girelli G; Guarnieri A; Meattini I; Ricardi U; Mangoni M; Gabriele P; Bellavita R; Krengli M; Bonetta A; Cagna E; Bunkheila F; Borghesi S; Signor M; Di Marco A; Bertoni F; Stefanacci M; Gatta R; De Bari B; Magrini SM
Tumori; 2014; 100(1):31-7. PubMed ID: 24675488
[TBL] [Abstract][Full Text] [Related]
7. Moderately hypofractionated radiotherapy for localized prostate cancer: updated long-term outcome and toxicity analysis.
Tamihardja J; Schortmann M; Lawrenz I; Weick S; Bratengeier K; Flentje M; Guckenberger M; Polat B
Strahlenther Onkol; 2021 Feb; 197(2):124-132. PubMed ID: 32833036
[TBL] [Abstract][Full Text] [Related]
8. Intensity-modulated radiotherapy for the treatment of prostate cancer: a systematic review and economic evaluation.
Hummel S; Simpson EL; Hemingway P; Stevenson MD; Rees A
Health Technol Assess; 2010 Oct; 14(47):1-108, iii-iv. PubMed ID: 21029717
[TBL] [Abstract][Full Text] [Related]
9. Comparison of dose-escalated, image-guided radiotherapy vs. dose-escalated, high-dose-rate brachytherapy boost in a modern cohort of intermediate-risk prostate cancer patients.
Marina O; Gustafson GS; Kestin LL; Brabbins DS; Chen PY; Ye H; Martinez AA; Ghilezan MI; Wallace M; Krauss DJ
Brachytherapy; 2014; 13(1):59-67. PubMed ID: 23871661
[TBL] [Abstract][Full Text] [Related]
10. Radiation dose escalation for localized prostate cancer: intensity-modulated radiotherapy versus permanent transperineal brachytherapy.
Wong WW; Vora SA; Schild SE; Ezzell GA; Andrews PE; Ferrigni RG; Swanson SK
Cancer; 2009 Dec; 115(23):5596-606. PubMed ID: 19670452
[TBL] [Abstract][Full Text] [Related]
11. Decreased acute toxicities of intensity-modulated radiation therapy for localized prostate cancer with prostate-based versus bone-based image guidance.
Nakamura K; Mizowaki T; Inokuchi H; Ikeda I; Inoue T; Kamba T; Ogawa O; Hiraoka M
Int J Clin Oncol; 2018 Feb; 23(1):158-164. PubMed ID: 28756594
[TBL] [Abstract][Full Text] [Related]
12. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcome of a moderately hypofractionated, intensity-modulated radiotherapy approach using an endorectal balloon for patients with localized prostate cancer.
Teh BS; Lewis GD; Mai W; Pino R; Ishiyama H; Butler EB
Cancer Commun (Lond); 2018 Apr; 38(1):11. PubMed ID: 29764515
[TBL] [Abstract][Full Text] [Related]
14. Timing of High-Dose Rate Brachytherapy With External Beam Radiotherapy in Intermediate and High-Risk Localized Prostate CAncer (THEPCA) Patients and Its Effects on Toxicity and Quality of Life: Protocol of a Randomized Feasibility Trial.
Palvai S; Harrison M; Shibu Thomas S; Hayden K; Green J; Anderson O; Romero L; Lodge R; Burns P; Ahmed I
JMIR Res Protoc; 2015 Apr; 4(2):e49. PubMed ID: 25926023
[TBL] [Abstract][Full Text] [Related]
15. Target miss using PTV-based IMRT compared to robust optimization via coverage probability concept in prostate cancer.
Outaggarts Z; Wegener D; Berger B; Zips D; Paulsen F; Bleif M; Thorwarth D; Alber M; Dohm O; Müller AC
Acta Oncol; 2020 Aug; 59(8):911-917. PubMed ID: 32436467
[No Abstract] [Full Text] [Related]
16. Image Guided Hypofractionated Postprostatectomy Intensity Modulated Radiation Therapy for Prostate Cancer.
Lewis SL; Patel P; Song H; Freedland SJ; Bynum S; Oh D; Palta M; Yoo D; Oleson J; Salama JK
Int J Radiat Oncol Biol Phys; 2016 Mar; 94(3):605-11. PubMed ID: 26867889
[TBL] [Abstract][Full Text] [Related]
17. Moderate Hypofractionation with Simultaneous Integrated Boost in Prostate Cancer: Long-term Results of a Phase I-II Study.
Di Muzio NG; Fodor A; Noris Chiorda B; Broggi S; Mangili P; Valdagni R; Dell'Oca I; Pasetti M; Deantoni CL; Chiara A; Berardi G; Briganti A; Calandrino R; Cozzarini C; Fiorino C
Clin Oncol (R Coll Radiol); 2016 Aug; 28(8):490-500. PubMed ID: 26961088
[TBL] [Abstract][Full Text] [Related]
18. Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer.
Fonteyne V; De Gersem W; De Neve W; Jacobs F; Lumen N; Vandecasteele K; Villeirs G; De Meerleer G
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1013-20. PubMed ID: 19386427
[TBL] [Abstract][Full Text] [Related]
19. Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V.
Michalski JM; Winter K; Purdy JA; Parliament M; Wong H; Perez CA; Roach M; Bosch W; Cox JD
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):706-13. PubMed ID: 15936549
[TBL] [Abstract][Full Text] [Related]
20. Hypofractionated Dose Escalated 3D Conformal Radiotherapy for Prostate Cancer: Outcomes from a Mono-Institutional Phase II Study.
Tramacere F; Arcangeli S; Pignatelli A; Castagna R; Portaluri M
Anticancer Res; 2015 May; 35(5):3049-54. PubMed ID: 25964594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
